3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
3
Recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Dermatologic
39
Gynecologic
12
CNS
5
Breast
4
Other neoplasm
3
Lymphoid
3
Gastrointestinal
3
Other hematologic neoplasm
2
Genitourinary
2
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Stomach Neoplasms
1
Squamous Intraepithelial Lesions
1
Papillomavirus Infections
1
HIV Infections
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Anus Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
Fluorouracil
616
Oxaliplatin
579
Gemcitabine
492
Capecitabine
445
Leucovorin
427
Irinotecan
390
Bevacizumab
330
Cisplatin
320
Radiotherapy
245
Cetuximab
215
Sorafenib
167
pembrolizumab
152
Docetaxel
150
Paclitaxel
140
Nivolumab
128
Albumin-Bound Paclitaxel
108
130-nm albumin-bound paclitaxel
108
Folfox protocol
101
Panitumumab
95
Erlotinib Hydrochloride
95
Surgical Procedures, Operative
86
regorafenib
84
S 1 (combination)
81
Drug Therapy
80
Radiation
69
Carboplatin
65
Neoadjuvant Therapy
64
Colonoscopy
64
Radiosurgery
63
Surveys and Questionnaires
60
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Completed
×
Imiquimod
×
Gastrointestinal
×
Clear all
NCT02135419
2024-07-26
ANCHOR
AIDS Malignancy Consortium
Phase 3
Completed
4,446 enrolled
13 charts
NCT02276300
2019-11-20
HER2
Technical University of Munich
Phase 1
Completed
2 enrolled
NCT00785122
2013-05-16
IMA910-101
Immatics Biotechnologies GmbH
Phase 1/2
Completed
92 enrolled